nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-46A09CAD·Framework v5.8·Pipeline v0.4·Evaluated 18 Aug 2026·OECD: 3.2 Clinical medicine·Subfield: Molecular Biology·Basis: Full text·Type: Narrative review

An Overview of Nrf2 Signaling Pathway and Its Role in Inflammation.

Saha et al.Saha, Buttari, Panieri et al.·2020·Molecules (Basel, Switzerland)·10.3390/molecules25225474 ↗

Primary claim

Nrf2 and its principal negative regulator, the E3 ligase adaptor Kelch-like ECH-associated protein 1 (Keap1), play a central role in the maintenance of intracellular redox homeostasis and regulation of inflammation

Supported · extensive mechanistic and preclinical literature supports the direction, though heterogeneous models and unreported source selection limit certainty
In brief

A broad, useful map of Nrf2–inflammation biology whose catalog-like synthesis stops short of resolving the field’s central contradictions.

ReliabilityCaveats4 of 4 checks completeRead the entry ↓
Abstract

Inflammation is a key driver in many pathological conditions such as allergy, cancer, Alzheimer's disease, and many others, and the current state of available drugs prompted researchers to explore new therapeutic targets. In this context, accumulating evidence indicates that the transcription factor Nrf2 plays a pivotal role controlling the expression of antioxidant genes that ultimately exert anti-inflammatory functions. Nrf2 and its principal negative regulator, the E3 ligase adaptor Kelch-like ECH- associated protein 1 (Keap1), play a central role in the maintenance of intracellular redox homeostasis and regulation of inflammation. Interestingly, Nrf2 is proved to contribute to the regulation of the heme oxygenase-1 (HO-1) axis, which is a potent anti-inflammatory target. Recent studies showed a connection between the Nrf2/antioxidant response element (ARE) system and the expression of inflammatory mediators, NF-κB pathway and macrophage metabolism. This suggests a new strategy for designing chemical agents as modulators of Nrf2 dependent pathways to target the immune response. Therefore, the present review will examine the relationship between Nrf2 signaling and the inflammation as well as possible approaches for the therapeutic modulation of this pathway.

Key Claims

Primary finding · Supported

Nrf2 and its principal negative regulator, the E3 ligase adaptor Kelch-like ECH-associated protein 1 (Keap1), play a central role in the maintenance of intracellular redox homeostasis and regulation of inflammation

extensive mechanistic and preclinical literature supports the direction, though heterogeneous models and unreported source selection limit certainty

Abstract
Quote verified
Secondary · Tentative

Nrf2 is proved to contribute to the regulation of the heme oxygenase-1 (HO-1) axis, which is a potent anti-inflammatory target

categorical wording exceeds a synthesis that acknowledges context dependence and unresolved molecular mechanisms

Abstract
Quote verified
Secondary · Supported

Nrf2 negatively controls the NF-κB signaling pathway by multiple mechanisms

multiple cited mechanisms support the direction, while Section 3 documents important context-specific exceptions

Section 3
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Broad integration across inflammatory mechanisms

The review links Nrf2–Keap1 biochemistry with NF-κB, HO-1, cytokines, adhesion molecules, proteases, inflammasomes, and pharmacological modulators in a single narrative.

↳ Sections 2–7

#positioning

Contradictory evidence is directly acknowledged

Section 3 presents opposing findings on Nrf2 and NF-κB family expression, while Section 5 foregrounds evidence that Nrf2 can either suppress or support inflammasome activation.

↳ Sections 3 and 5

#application pathway

Visible pathway from mechanism to therapeutics

Section 6 connects molecular mechanisms to approved DMF use and additional clinical-stage fumarate programs, making the translational pathway concrete.

↳ Section 6

Limitations

#methodological rigour

No reported source-selection methodology

The article provides no databases, date range, inclusion criteria, or explanation of how its extensive literature was identified and selected.

↳ Absence of a Methods or search-strategy section

#contribution

Contradictions catalogued rather than resolved

Sections 3 and 5 identify central contradictions but stop at describing them, without a framework for determining when Nrf2 enhances or suppresses inflammation.

↳ Sections 3 and 5

#reporting

Abstract language overstates mechanistic certainty

The Abstract calls the Nrf2–HO-1 relationship “proved,” while Sections 3–5 describe cell-specific effects, unresolved mechanisms, and controversial inflammasome findings.

↳ Abstract; Sections 3, 4.1, and 5

Does this match your read? Add your assessment ↓

Nabu Commentary

The article’s strongest feature is its breadth, moving from Nrf2–Keap1 signaling to NF-κB cross-talk, inflammatory mediators, inflammasomes, and therapeutic candidates. Sections 3 and 5 improve balance by presenting findings in which Nrf2 can support rather than suppress inflammatory signaling. The score is constrained by the absence of any search or source-selection method and by the largely descriptive treatment of those contradictions. Section 8 identifies important translational limitations, but Section 9 still advances a broad therapeutic-potential conclusion without fully incorporating them.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.1±0.2

Contribution
2.9

The review consolidates Nrf2–Keap1, NF-κB, HO-1, inflammasome, and pharmacological evidence into one broad account. Its contribution remains limited because it identifies but does not resolve the principal contradictions it surveys.

Sections 3, 5, and 9

it is still controversial whether activation of Nrf2 can lead to the prevention or the induction of aggressive inflammation

Methodological Rigour
2.9

The progression from pathway biology to inflammatory mediators and therapeutics is coherent, and contrary findings receive explicit attention. The article nevertheless operates mainly as a study catalog and reports no search strategy, inclusion criteria, databases, or date range.

Sections 2–7; absence of a Methods or search-strategy section

These conflicting results suggest the need to focus on the role of unknown functions of Nrf2 signaling pathway

Reporting
3.6

Section ordering makes the mechanistic argument followable despite dense terminology and long sequences of individual studies. Precision is reduced by the Abstract’s claim that the Nrf2–HO-1 relationship is “proved” while later sections acknowledge unresolved mechanisms and context dependence.

Abstract; Sections 3, 4.1, and 5

Nrf2 is proved to contribute to the regulation of the heme oxygenase-1 (HO-1) axis

Positioning
3.4

The review engages a large literature and directly presents conflicting NF-κB and NLRP3 findings rather than depicting the field as settled. Cancer risk, off-target effects, blood–brain barrier limitations, and clinical-validation needs are acknowledged, but their implications are not deeply integrated into the therapeutic conclusion.

Sections 3, 5, 8, and 9

More detailed studies are necessary to better characterize potential safety issues

Reliability

Caveats4 of 4 checks


Internal CoherenceNoted

The central argument remains coherent, but the Abstract contains localized overstatement and the body has citation-format inconsistencies. These issues do not reverse the review’s main interpretation.

Research ConductClean

As a narrative review presenting no original human or animal experiments, the article raises no applicable ethics, registration, data, or code conduct concern in the supplied text.

Flags: 0 declared / 5 total

Reference IntegrityClean

268 of 268 checkable references verified

268 references in manuscript citation details diverge from the cited records for 1 reference

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Generic health relevance
Type of advanceSynthesis
Route to useSuggested
AdvanceConsolidates
CitationsFWCI 42.5
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessControlled
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The strongest evidence synthesised for the claim comes from cell lines and knockout animal models, without independent human confirmation of the broad inflammation-regulation role.

From the paper
“support the hypothesis that Nrf2 inducers have the strong potential as anti-inflammatory therapeutic agents”

The review names a possible real-world use of Nrf2 findings as anti-inflammatory therapeutic agents, but does not specify who would act on them or in what decision setting.

Pathway

Pharmaceutical companies and medicinal chemists would exploit Nrf2-Keap1 biology to design and screen small-molecule Nrf2 modulators as anti-inflammatory drugs.

Barrier

Conflicting evidence on Nrf2's pro- versus anti-inflammatory roles, unresolved safety concerns with sustained activation, and lack of rigorous clinical validation block translation.

Evaluated 12 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Personalized redox medicine in inflammatory bowel diseases: an emerging role for HIF-1α and NRF2 as therapeutic targets

    Arno R. Bourgonje, Damian Klóska, Anna Grochot‐Przeczek, et al. · 2023 · Clinical medicine

    Evidence Score
    3.4±0.2
    Reliability
    No concerns
  2. A Protective Role of the NRF2-Keap1 Pathway in Maintaining Intestinal Barrier Function

    Zhiyong Wen, Weihua Liu, Xing Li, et al. · 2019 · Basic medicine

    Primary claim

    NRF2 reduced intestinal mucosal injury by suppressing oxidative stress

    Supported
    Evidence Score
    2.6±0.2
    Reliability
    Caveats
  3. The NRF2/Keap1 pathway as a therapeutic target in inflammatory bowel disease

    Sem Geertsema, Arno R. Bourgonje, Raphael R. Fagundes, et al. · 2023 · Clinical medicine

    Primary claim

    Preclinical evidence supports targeted therapeutic modulation of the NRF2/Keap1 pathway in the gastrointestinal tract, albeit human evidence is scarce.

    Tentative
    Evidence Score
    3.1±0.2
    Reliability
    No concerns

How the rubric works →